Exscientia plc (EXAI) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Oxford, イギリス. 現CEOは David Hallett.
EXAI を有する IPO日 2021-10-01, 483 名の正社員, に上場 NASDAQ Global Select, 時価総額 $633.18M.
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
